17416-87-4

Basic information

• Product Name: 6-[(diphenylmethyl)sulfanyl]-5H-purine
• CAS NO: 17416-87-4
• Molecular Formula: C₁₈H₁₄N₄S
• Molecular Weight: 318.3956
• Mol File: 17416-87-4.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 476.2°C at 760 mmHg
• Flash Point: 241.8°C
• Density: 1.31g/cm³
• Vapor Pressure: 8.96E-09mmHg at 25°C
• Refractive Index: 1.718
• CAS DataBase Reference: 6-[(diphenylmethyl)sulfanyl]-5H-purine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-[(diphenylmethyl)sulfanyl]-5H-purine(17416-87-4)
• EPA Substance Registry System: 6-[(diphenylmethyl)sulfanyl]-5H-purine(17416-87-4)

Safety Data

• Hazardous Substances Data: 17416-87-4(Hazardous Substances Data)

Upstream product

• 776-74-9 Bromodiphenylmethane 
• 50-44-2 6-mercapto-purine 
• 50-44-2 6-mercaptopurine 
• 157930-09-1 6-Mercaptopurine 

Downstream Products

• 1401081-58-0 C₄₄H₅₇N₁₃O₇S 
• 1401081-47-7 C₂₄H₂₆N₄O₃S 
• 84691-71-4 9-<3-(thym-1-yl)propyl>-6-diphenylmethylthiopurine 
• 84691-72-5 9-propyl-6-diphenylmethylthiopurine 

Relevant articles and documents

PRODRUGS OF ANTI-CANCER AND ANTI-AUTOIMMUNE DISEASES THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USE THEREOF

The invention relates to prodrugs of anti-cancer and anti-autoimmune diseases therapeutic agents, and methods of making and use thereof.

TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS

The invention relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. The invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. The invention also provides methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1 B1 and allelic variants thereof. The invention also provides a method for determining the efficacy of a compound of the invention in treating cancer.